Skip to main content

Table 4 Median OS, median PFS in first-line of treatment and median PFS in second-line of treatment by treatment sequences in the overall population and by subgroups defined upon immunohistochemical characterization of molecules features (N:5555)

From: Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us